Table 1.
Demographics and clinical characteristics of patients.
| aHUS patients | Other diagnoses | P | |
|---|---|---|---|
| n | 14 | 179126 | |
| Donor age in years (median [IQR]) | 46.00 [35.50, 54.00] | 40.00 [27.00, 51.00] | 0.199 |
| Donor sex n (%) | |||
| Unknown | N≤10 (57.1) | 64983 (36.3) | |
| Female | N≤10 (35.7) | 45190 (25.2) | |
| Male | N≤10 (7.1) | 68953 (38.5) | |
| Donor race n (%) | |||
| Native American | N≤10 (0) | 887 (0.5) | |
| Asian | N≤10 (0) | 4977 (2.8) | |
| Black | N≤10 (0) | 24026 (13.4) | |
| White | 14 (100) | 148225 (82.7) | |
| Unknown | N≤10 (0) | 1011 (0.6) | |
| Living donor n (%) | N≤10 (57.1) | 64983 (36.3) | 0.178 |
| Recipient age in years (median [IQR]) | 35.00 [27.00, 49.00] | 52.00 [39.00, 61.00] | 0.002 |
| Recipient BMI (median [IQR]) | 27.08 [22.40, 28.83] | 27.02 [23.33, 31.28] | 0.427 |
| Recipient most recent creatinine (median [IQR]) | 8.50 [6.25, 11.50] | 7.10 [5.10, 9.60] | 0.162 |
| Recipient race n (%) | |||
| Native American | N≤10 (0) | 1652 (0.9) | |
| Asian | N≤10 (0) | 9783 (5.5) | |
| Black | N≤10 (21.4) | 45117 (25.2) | |
| White | 11 (78.6) | 121227 (67.7) | |
| Unknown | N≤10 (0) | 1347 (0.8) | |
| Recipient – Male n (%) | N≤10 (28.6) | 109181 (61.0) | |
| One or two HLA mismatches n (%) | N≤10 (42.9) | 35297 (19.7) | 0.066 |
| Peak PRA (median [IQR]) | 37.00 [12.75, 69.50] | 32.00 [10.00, 77.00] | 0.993 |
| Induction immunosuppression n (%) | |||
| Cyclosporin | N≤10 (57.1) | 73455 (41.0) | 0.339 |
| Tacrolimus | N≤10 (28.6) | 15568 (8.7) | |
| Sirolimus | 12 (85.7) | 136794 (76.4) | 0.611 |
| Everolimus | N≤10 (0) | 3716 (2.1) | |
| Azathioprine | N≤10 (0) | 81 (0.0) | |
| Mycophenolate mofetil | N≤10 (14.3) | 28780 (16.1) | |
| Corticosteroids | N≤10 (0) | 180 (0.1) | |
| Cyclophosphamide | 11 (78.6) | 112145 (62.6) | |
| Methotrexate | N≤10 (0) | 40 (0.0) | |
| Antilymphocyte globulin | N≤10 (0) | 1632 (0.9) | |
| Antithymocyte globulin | N≤10 (0) | 3223 (1.8) | |
| IL2-receptor antagonists | N≤10 (0) | 4 (0.0) | |
| Nucleotide synthesis inhibitors | N≤10 (14.3) | 8428 (4.7) | |
| Anti-CD3 antibody | N≤10 (0) | 56 (0.0) | |
| Anti-IL2 antibody | N≤10 (35.7) | 92431 (51.6) | 0.357 |
| Rituximab | N≤10 (0) | 81 (0.0) | |
| Alemtuzumab | 14 (100) | 166265 (92.8) | |
| Other antibody | N≤10 (0) | 3127 (1.7) | |
| Other IL2 antibody | N≤10 (0) | 13 (0.0) | |
| Other | N≤10 (57.1) | 40138 (22.4) | 0.005 |
| Maintenance immunosuppression (n (%)) | |||
| Cyclosporin | N≤10 (21.4) | 27478 (15.3) | |
| Tacrolimus | 12 (85.7) | 145677 (81.3) | 0.938 |
| Sirolimus | N≤10 (35.7) | 20593 (11.5) | 0.015 |
| Everolimus | N≤10 (0) | 1501 (0.8) | |
| Azathioprine | N≤10 (28.6) | 13079 (7.3) | |
| Mycophenolate mofetil | 13 (92.9) | 151767 (84.7) | 0.635 |
| Corticosteroids | 14 (100) | 125087 (69.8) | 0.030 |
| Cyclophosphamide | N≤10 (0) | 204 (0.1) | |
| Methotrexate | N≤10 (0) | 133 (0.1) | |
| Antilymphocyte globulin | N≤10 (0) | 318 (0.2) | |
| Antithymocyte globulin | N≤10 (0) | 5650 (3.2) | |
| IL-1R agents | N≤10 (0) | 25 (0.0) | |
| Nucleotide synthesis inhibitors | N≤10 (0) | 3421 (1.9) | |
| Anti-CD3 antibody | N≤10 (0) | 2136 (1.2) | |
| Anti-IL2 antibody | N≤10 (0) | 540 (0.3) | |
| Rituximab | N≤10 (7.1) | 1458 (0.8) | |
| Alemtuzumab | N≤10 (0) | 259 (0.1) | |
| Other antibody | N≤10 (0) | 65 (0.0) | |
| Other IL2 | N≤10 (0) | 51 (0.0) | |
| Other | N≤10 (35.7) | 7452 (4.2) | <0.001 |